October 11, 2021
Sandoz completes acquisition of GSK’s cephalosporin business
Sandoz, a Novartis division, has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets,…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novartis
September 30, 2021
Novartis data show rapid and effective disease activity control with remibrutinib in patients with chronic spontaneous urticaria
Novartis today announced positive Phase IIb data showing remibrutinib (LOU064), a potentially best-in-class oral BTK inhibitor, demonstrated rapid and effective disease control in patients with inadequately controlled chronic spontaneous urticaria (CSU).
September 29, 2021
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life
Novartis’ dana from new analysis from a Phase IIb study has showed the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients, as complete control of symptoms brings enormous benefit to people with CSU and is associated with improvements in key HRQoL measures such as overall quality of life, sleep interference, activity interference and work impairment.
September 20, 2021
Novartis, Harmonia move to Phase III trial to test Kisqali vs. Ibrance in patients with advanced breast cancer
Novartis said Monday it has started a collaboration with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase III, multicenter, open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib),.
September 13, 2021
USFDA accepts Novartis’ tislelizumab for people with esophageal cancer
Novartis got an acceptance by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy.
June 22, 2021
Mean IgG levels in people treated with Kesimpta remained unchanged over 3.5 years
On Tuesday, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab) over 3.5 years.
March 9, 2021
Novartis’ Phase III CANOPY-2 trial misses goal
Novartis said Tuesday its Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments.
September 8, 2020
Novartis presentation includes new data on recently FDA-approved Kesimpta
Novartis will present 48 abstracts at the upcoming MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, September 11–13, 2020. The breadth of data being presented highlights the strength and promise of the company’s MS portfolio to improve the lives of patients across the MS spectrum.
May 29, 2020
Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)
Data from Phase III EXPAND trial, continue to build on existing clinical evidence that Mayzent has significant impact on reducing the risk of disease progression, including physical disability and cognitive decline for patients with SPMS.
May 11, 2020
Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
Dyno Therapeutics has entered collaboration with Novartis, to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases.